| 000 | 01802 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516235636.0 | ||
| 264 | 0 | _c20161213 | |
| 008 | 201612s 0 0 eng d | ||
| 022 | _a1724-6059 | ||
| 024 | 7 |
_a10.1007/s40620-014-0147-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTakahashi, Aya | |
| 245 | 0 | 0 |
_aAngiotensin II type 1 receptor blockade ameliorates proteinuria in puromycin aminonucleoside nephropathy by inhibiting the reduction of NEPH1 and nephrin. _h[electronic resource] |
| 260 |
_bJournal of nephrology _cDec 2014 |
||
| 300 |
_a627-34 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAngiotensin II Type 1 Receptor Blockers _xpharmacology |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBiphenyl Compounds _xpharmacology |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Expression Regulation |
| 650 | 0 | 4 |
_aIntracellular Signaling Peptides and Proteins _xmetabolism |
| 650 | 0 | 4 | _aIrbesartan |
| 650 | 0 | 4 |
_aKidney Glomerulus _xdrug effects |
| 650 | 0 | 4 |
_aMembrane Proteins _xgenetics |
| 650 | 0 | 4 |
_aNephrosis, Lipoid _xchemically induced |
| 650 | 0 | 4 |
_aProteinuria _xchemically induced |
| 650 | 0 | 4 | _aPuromycin Aminonucleoside |
| 650 | 0 | 4 | _aRats, Wistar |
| 650 | 0 | 4 |
_aReceptor, Angiotensin, Type 1 _xdrug effects |
| 650 | 0 | 4 |
_aTetrazoles _xpharmacology |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aFukusumi, Yoshiyasu | |
| 700 | 1 | _aYamazaki, Mihoko | |
| 700 | 1 | _aKayaba, Mutsumi | |
| 700 | 1 | _aKitazawa, Yukina | |
| 700 | 1 | _aTomita, Masayuki | |
| 700 | 1 | _aKawachi, Hiroshi | |
| 773 | 0 |
_tJournal of nephrology _gvol. 27 _gno. 6 _gp. 627-34 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s40620-014-0147-z _zAvailable from publisher's website |
| 999 |
_c24262261 _d24262261 |
||